Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Opening soon Phase 3 NCT07441408
Run by Bristol-Myers Squibb · for All ages · All sexes
What this study is about
The purpose of this study is to evaluate the long-term safety and tolerability of Admilparant in participants who completed participation in parent studies IM027-068 (for idiopathic pulmonary fibrosis (IPF)) and IM027-1015 (for progressive pulmonary fibrosis (PPF)).
Who can join (things the study team will check)
✅ You may be able to join if…
- Participants must have completed participation in either IM027068 or IM0271015 (defined as receiving study intervention (IMP) until completion of EOT visit).
🚫 You may not be able to join if…
- Clinically significant AE that resulted in discontinuation or interruption of IMP (Investigational Medicinal Product) in IM027068 or IM0271015 without reinitiation of IMP.
- Exhibit symptoms of heart failure at rest.
- History of lung reduction surgery or lung transplant. Note: Being on the transplantation list is allowed.
- Participants with known PAH (Pulmonary Arterial Hypertension) who has been on single drug therapy that now requires multi-drug therapy.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where this trial is running
- Local Institution - 0113, Birmingham, Alabama, United States
- Local Institution - 0111, Ocala, Florida, United States
- Local Institution - 0119, Philadelphia, Pennsylvania, United States
- Local Institution - 0013, Florida, Vicente López, Buenos Aires, Argentina
- Local Institution - 0014, Mar del Plata, Buenos Aires, Argentina
- Local Institution - 0007, Quilmes, Buenos Aires, Argentina
- Local Institution - 0009, San Juan Bautista, Buenos Aires, Argentina
- Local Institution - 0003, Mar del Plata, B, Argentina
- Local Institution - 0001, Córdoba, Córdoba Province, Argentina
- Local Institution - 0005, CABA, Distrito Federal, Argentina
- Local Institution - 0002, Godoy Cruz, Mendoza Province, Argentina
- Local Institution - 0011, Mendoza, M, Argentina
+ 263 more sites.
Who to contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07441408.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.